JP2013512866A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013512866A5 JP2013512866A5 JP2012541362A JP2012541362A JP2013512866A5 JP 2013512866 A5 JP2013512866 A5 JP 2013512866A5 JP 2012541362 A JP2012541362 A JP 2012541362A JP 2012541362 A JP2012541362 A JP 2012541362A JP 2013512866 A5 JP2013512866 A5 JP 2013512866A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- ferlin
- epitope
- antigenic determinant
- plasmodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 89
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 230000000890 antigenic effect Effects 0.000 claims description 57
- 102000056303 Ferlin Human genes 0.000 claims description 35
- 108700036130 Ferlin Proteins 0.000 claims description 35
- 241000223960 Plasmodium falciparum Species 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 27
- 241000224016 Plasmodium Species 0.000 claims description 22
- 241000224017 Plasmodium berghei Species 0.000 claims description 21
- 101000933074 Arabidopsis thaliana Protein C2-DOMAIN ABA-RELATED 4 Proteins 0.000 claims description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 8
- 241000223996 Toxoplasma Species 0.000 claims description 6
- 201000004792 malaria Diseases 0.000 claims description 4
- 229940124735 malaria vaccine Drugs 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 39
- 241000209504 Poaceae Species 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 241000223997 Toxoplasma gondii Species 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000002671 adjuvant Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000002539 nanocarrier Substances 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 238000011191 terminal modification Methods 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 101710091045 Envelope protein Proteins 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 101710188315 Protein X Proteins 0.000 claims 1
- 102100021696 Syncytin-1 Human genes 0.000 claims 1
- 230000005867 T cell response Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000002925 dental caries Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 241000224482 Apicomplexa Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 230000026502 entry into host cell Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26702609P | 2009-12-05 | 2009-12-05 | |
| US61/267,026 | 2009-12-05 | ||
| PCT/EP2010/007399 WO2011066995A1 (en) | 2009-12-05 | 2010-12-06 | Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013512866A JP2013512866A (ja) | 2013-04-18 |
| JP2013512866A5 true JP2013512866A5 (cg-RX-API-DMAC10.html) | 2017-01-26 |
Family
ID=43499977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012541362A Pending JP2013512866A (ja) | 2009-12-05 | 2010-12-06 | アピコンプレクサＦｅｒｌｉｎ、Ｆｅｒｌｉｎ様タンパク質、及び他のＣ２ドメイン含有タンパク質に基づくマラリアワクチン |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8968750B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2507259B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2013512866A (cg-RX-API-DMAC10.html) |
| CN (1) | CN102781958B (cg-RX-API-DMAC10.html) |
| BR (1) | BR112012013581A8 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2783107C (cg-RX-API-DMAC10.html) |
| MX (1) | MX2012006458A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2011066995A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012076157A2 (en) | 2010-12-06 | 2012-06-14 | Ruprecht-Karls-Universität Heidelberg | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
| EP2941269B1 (en) * | 2013-01-07 | 2020-12-09 | Mucosal Vaccine Technologies LLC | Therapeutic vaccines for treating herpes simplex virus type 2 infections |
| CA2957722C (en) | 2014-08-19 | 2022-05-31 | Merck Sharp & Dohme Corp. | Anti-tigit antibodies |
| CN115925931A (zh) | 2015-08-14 | 2023-04-07 | 默沙东公司 | 抗tigit抗体 |
| JP2017210441A (ja) * | 2016-05-26 | 2017-11-30 | 国立大学法人大阪大学 | マラリアワクチン |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4518528A (en) * | 1983-05-19 | 1985-05-21 | Rasnick David W | α Amino fluoro ketones |
| US5198334A (en) * | 1989-07-21 | 1993-03-30 | Terumo Corporation | Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells |
| GB9406492D0 (en) * | 1994-03-31 | 1994-05-25 | Isis Innovation | Malaria peptides |
| AU5931698A (en) * | 1997-01-21 | 1998-08-07 | New York University | Universal t-cell epitopes for anti-malarial vaccines |
| US20030077653A1 (en) * | 2000-04-20 | 2003-04-24 | The University Of Georgia Research Foundation, Inc. | Method for the identification of active site protease inactivators |
| US7811575B2 (en) * | 2001-04-10 | 2010-10-12 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer |
| GB0210128D0 (en) * | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| CA2409897A1 (en) * | 2002-10-25 | 2004-04-25 | Institut Pasteur | Plasmodium falciparum virulence factor var o |
| US7198791B2 (en) * | 2003-03-03 | 2007-04-03 | Pluschke, Gerd Et Al. | Compositions and methods for the generation of protective immune responses against malaria |
| US8206725B2 (en) * | 2003-08-26 | 2012-06-26 | The Council Of The Queensland Institute Of Medical Research | Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP |
| US20090324628A1 (en) * | 2003-12-30 | 2009-12-31 | Kobenhavns Universitet Panium | Compounds useful in the diagnosis and treatment of malaria |
| JP4834671B2 (ja) * | 2005-09-29 | 2011-12-14 | 株式会社マルハニチロ水産 | 成人病の予防及び治療に有効な組成物 |
| GB0601059D0 (en) * | 2006-01-19 | 2006-03-01 | Univ Durham | Target |
| WO2009082440A2 (en) * | 2007-12-18 | 2009-07-02 | Vaxinnate Corporation | Compositions of toll-like receptor agonists and malaria antigens and methods of use |
| US8343498B2 (en) * | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
| US8343497B2 (en) * | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
| US8277812B2 (en) * | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| WO2011085070A2 (en) * | 2010-01-06 | 2011-07-14 | Virginia Tech Intellectual Properties, Inc. | Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts |
| WO2012076157A2 (en) * | 2010-12-06 | 2012-06-14 | Ruprecht-Karls-Universität Heidelberg | Malaria vaccines based on pre-erythrocytic antigens from p. falciparum |
-
2010
- 2010-12-06 BR BR112012013581A patent/BR112012013581A8/pt not_active Application Discontinuation
- 2010-12-06 CA CA2783107A patent/CA2783107C/en not_active Expired - Fee Related
- 2010-12-06 US US13/513,059 patent/US8968750B2/en active Active
- 2010-12-06 MX MX2012006458A patent/MX2012006458A/es unknown
- 2010-12-06 JP JP2012541362A patent/JP2013512866A/ja active Pending
- 2010-12-06 CN CN201080063115.5A patent/CN102781958B/zh not_active Expired - Fee Related
- 2010-12-06 EP EP10787325.9A patent/EP2507259B1/en not_active Not-in-force
- 2010-12-06 WO PCT/EP2010/007399 patent/WO2011066995A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kaba et al. | A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria | |
| Mettens et al. | Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS, S vaccine antigen | |
| Nardin et al. | Plasmodium falciparum polyoximes: highly immunogenic synthetic vaccines constructed by chemoselective ligation of repeat B-cell epitopes and a universal T-cell epitope of CS protein | |
| JP2012501959A5 (cg-RX-API-DMAC10.html) | ||
| JP2023513720A5 (cg-RX-API-DMAC10.html) | ||
| JP7261013B2 (ja) | マラリアワクチンにおいて使用するための新規抗原 | |
| CN1241639C (zh) | 抵抗疟疾的疫苗组合物 | |
| JP2021519599A (ja) | 抗原性ｏｓｐａポリペプチド | |
| JP2013527760A5 (cg-RX-API-DMAC10.html) | ||
| JP2016146837A5 (cg-RX-API-DMAC10.html) | ||
| RU2012114483A (ru) | Вирусоподобные частицы, содержащие белки-мишени, слитые с белками оболочки растительных вирусов | |
| JP2014507146A5 (cg-RX-API-DMAC10.html) | ||
| TW201803907A (zh) | 作為抗瘧疾疫苗之生物融合蛋白 | |
| Yoshida et al. | A baculovirus dual expression system-based malaria vaccine induces strong protection against Plasmodium berghei sporozoite challenge in mice | |
| Teixeira et al. | Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents | |
| Li et al. | Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system | |
| RU2007109608A (ru) | Вакцины, содержащие антиген plasmodium | |
| Roggero et al. | The synthetic, oxidized C‐terminal fragment of the Plasmodium. berghei circumsporozoite protein elicits a high protective response | |
| JP2010535504A5 (cg-RX-API-DMAC10.html) | ||
| EA201171347A1 (ru) | Комбинированная вакцина против кори и малярии | |
| EP2915544B1 (en) | Chimeric vaccine antigens against hepatitis c virus | |
| CN113476600B (zh) | Avc-29作为疫苗佐剂的用途以及含有该佐剂的疫苗组合物 | |
| US9505812B2 (en) | Plasmodium falciparum antigens | |
| Reeder et al. | Strategic variants of CSP delivered as SynDNA vaccines demonstrate heterogeneity of immunogenicity and protection from Plasmodium infection in a murine model | |
| JP2018070571A (ja) | 免疫誘導剤 |